Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
Vlado Perkovic, Hiddo Lambers Heerspink, John Chalmers, Mark Woodward, Min Jun, Qiang Li, Stephen MacMahon, Mark E Cooper, Pavel Hamet, Michel Marre, Carl Erik Mogensen, Neil Poulter, Giuseppe Mancia, Alan Cass, Anushka Patel, Sophia Zoungas, undefined ADVANCE Collaborative Group
Kidney Int | Published : 2013
The effect of intensive glucose control on major kidney outcomes in type 2 diabetes remains unclear. To study this, the ADVANCE trial randomly assigned 11,140 participants to an intensive glucose-lowering strategy (hemoglobin A1c target 6.5% or less) or standard glucose control. Treatment effects on end-stage renal disease ((ESRD), requirement for dialysis or renal transplantation), total kidney events, renal death, doubling of creatinine to above 200 μmol/l, new-onset macroalbuminuria or microalbuminuria, and progression or regression of albuminuria, were then assessed. After a median of 5 years, the mean hemoglobin A1c level was 6.5% in the intensive group, and 7.3% in the standard group. ..View full abstract